Public Profile

Camurus

Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.

DitchCarbon Score

How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

41

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Camurus's score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.

75%

Let us know if this data was useful to you

Camurus's reported carbon emissions

In 2023, Camurus reported total carbon emissions of approximately 561,800 kg CO2e. This figure includes Scope 1 emissions of about 158,900 kg CO2e, primarily from mobile combustion, and Scope 2 emissions of approximately 11,680 kg CO2e. The company’s Scope 3 emissions were significant, totalling around 385,600 kg CO2e, with the largest contribution from downstream transportation and distribution, accounting for about 287,714 kg CO2e. Comparatively, in 2022, Camurus's total emissions were approximately 231,600 kg CO2e, with Scope 1 emissions at about 162,400 kg CO2e and Scope 2 emissions at approximately 16,690 kg CO2e. Scope 3 emissions for that year were around 60,300 kg CO2e, entirely from fuel and energy-related activities. Despite the increase in total emissions from 2022 to 2023, there are currently no publicly disclosed reduction targets or climate pledges from Camurus. The company has not specified any initiatives aimed at reducing its carbon footprint, which may be a consideration for stakeholders focused on sustainability.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
162,400
000,000
Scope 2
8,990
00,000
Scope 3
60,300
000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Camurus's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Camurus is in SE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Camurus is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Abeona Therapeutics Inc.

US
Health and social work services (85)
Updated 14 days ago

Td Medtekhnologii, Ooo

RU
Food products nec
Updated 14 days ago

Jazz Pharmaceuticals (EUSA Pharma USA) Inc.

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Fortovia Therapeutics, Inc.

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers